Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics
Epigenomics AG announced that it has entered into a non-exclusive licensing agreement for its proprietary biomarker mGSTP1 with U.S.-based Quest Diagnostics Incorporated. Under the agreement, Quest Diagnostics has obtained rights to uses of the GSTP1 DNA methylation biomarker (mGSTP1) to establish and commercialize a molecular-based laboratory-developed test that can help pathologists better diagnose prostate cancer based on testing of a patient's tissue specimen. Financial terms were not disclosed.
"We are pleased that Quest Diagnostics is expanding its menu of DNA methylation tests using our technologies and biomarkers. Quest Diagnostics has a strong record of innovation in diagnostics, including development of other DNA methylation diagnostic tests. They also share our goal to develop technologies that will help physicians achieve improved health outcomes for their patients through better diagnosis of prostate cancer and early detection of colorectal cancer", said Geert Nygaard, Chief Executive Officer of Epigenomics.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Major advances made in predicting crystal structures - Findings of international test have implications for pharmaceutical development
Frost: Strategic Analysis of the Opportunities for the Pharmaceutical and Biotechnology Industry in the 'New' EU Countries - Pharmaceutical and Biotechnology Industry in the 'New' EU Countries Presents Considerable Potential, Parallel Imports Remain a Challenge
Philips and Concateno Announce Revolutionary Drugs-of-Abuse Testing System
ESA Expands European Customer Service
BEAM | FT-NIR-Prozessspektrometer | Bruker
PerkinElmer and IDBS Announce Software Collaboration to Improve High Content Screening Outcomes for Drug Discovery Research
LUM moves location of US subsidiary LUM Corp. to Austin, TX
The 2011 Körber Prize goes to Stefan Hell - With a groundbreaking idea the physicist has overcome the diffraction resolution barrier in optical microscopy
ECHA publishes an updated list of pre-registered substances
NIST research highlights promise of AFM-IR for quantitative nanoscale chemical analysis.
Fritsch as Authorized Economic Operator (AEO-F) certified